NEW FRONTIERS
IN NEUROSCIENCE
Neurentis plc is a UK-based specialty pharmaceutical company established to identify, develop, and commercialise treatments for central nervous system disorders and rare neurodegenerative diseases. The company operates an asset-light, partnership-driven model, drawing on the extensive pharmaceutical industry experience of its leadership team to advance a diversified pipeline of clinical-stage and development-stage programmes.
Our focus areas include treatment-resistant depression, where our lead programme Quivara™ is preparing for a Phase III clinical trial, and orphan neurological conditions such as progressive supranuclear palsy, multiple system atrophy, and Perry syndrome, where patients currently have no approved treatment options. We are preparing for admission to trading on AIM, the London Stock Exchange's market for growth companies.
Expertise, Experience, Innovation.
Neurentis plc is a UK-based specialty pharmaceutical company focused on developing and licensing differentiated therapies for central nervous system disorders and rare neurodegenerative diseases.
Our pipeline comprises five programmes spanning late-stage clinical development, orphan drug candidates, a proprietary natural formulation, and artificial intelligence-driven drug discovery.
Our most advanced programme, Quivara (NRNT-012302), is a transdermal patch being advanced into a Phase III clinical trial for treatment-resistant depression, supported by a strategic collaboration with Viatris Inc., a leading global pharmaceutical company. Beyond Quivara, we are developing orphan drug candidates for progressive supranuclear palsy (NRNT-062501) and for multiple system atrophy and Perry syndrome (NRNT-072601), conditions where no approved treatments currently exist.
Pharma Market Potential
The global pharmaceutical market continues to grow, driven by ageing populations, rising prevalence of chronic and neurological conditions, and increasing investment in innovative treatments. Within this broader market, the neuroscience and rare disease segments have demonstrated particularly strong growth, with established regulatory frameworks that incentivise the development of treatments for conditions with high unmet medical need.
Learn More
Our Vision and Values
Our Vision, Values, Mission and Strategy are the foundation for our unique culture. These unify us in a common cause to improve the health of patients and lives of their families and other carers in a meaningful way by developing novel and innovative medicines and inspires us to make a positive contribution wherever we can.
OUR VISION: Our vision is to provide medicines of meaningful quality and value that improve the health of people suffering from serious neurological and psychiatric conditions, as well as the lives of their families and carers..
OUR VALUES: We are guided by integrity, intellectual honesty, and a commitment to data-driven decision making. We aspire to leadership in our areas of expertise, maintain a clear focus on our strategic objectives, and treat the company's assets with the same care and responsibility as our own. We value transparency, respect for all stakeholders, and a determination to deliver genuine clinical and commercial progress.
The Unmet Need in Our Focus Areas
Highlighting the needs in mental health